anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The utility model relates to a wetting agent type medicinal plaster for preventing the disease and is composed of nonwoven cloth 1, a leakage preventing layer 2, an adsorption layer 3, a powder bag 4, a leakage preventing ring 6 and a protecting layer 7, wherein the leakage preventing layer 2 is bonded with the nonwoven cloth 1 together. The leakage preventing layer 2 is compounded with the adsorption layer 3, and the powder bag 4 is positioned on the adsorption layer 3. The periphery of the powder bag 4 is cemented with the leakage preventing ring 6, and the leakage preventing ring 6 is bonded with the adsorption layer 3 together. The powder bag 4 and the leakage preventing ring 6 are covered with the protecting layer 7, and one layer of medical application kara paper 8 is positioned on the surface layer of the protecting layer 7 and the rest surface layer of the nonwoven cloth 1. The wetting agent type medicinal plaster for preventing the disease adapts the contour curve of a human body and does not disengage when the wetting agent type medicinal plaster for preventing the disease contacts water. The wetting agent type medicinal plaster for preventing the disease does not cause the clothes to be dirty easily, and the pledge life is long. The wetting agent type medicinal plaster for preventing the disease can prevent and treat various diseases, such as the coronary heart disease, the angina pectoris, etc. The wetting agent type medicinal plaster for preventing the disease has convenient processing operation and use and is the fine variety for replacing the older generation by new ones.
PROBLEM TO BE SOLVED: To establish an in vitro method for evaluating a hair growth agent having high correlation with in vivo by making hair papilla cells and hair follicle cells of animals coexist, culturing them, and taking the degree of their multiplication as an index. SOLUTION: Hair papilla cells and hair follicle cells of animals are made to coexist and cultured, and the degree of their multiplication is taken as an index. Animals with hair is used without any special limit as animals to be used, and mice, rats, etc., can be, for example, used. Especially from rats, it is easy to extract hair papilla cells and hair follicle cells, the reproducibility of evaluation is satisfactory, and they are inexpensive and easy to acquire. The use of whiskers, from which it is convenient to extract hair papilla cells and hair follicle cells aseptically and which is superior in correlation in screening and accuracy, is desirable as hair to be used.  In a method to extract hair papilla cells and hair follicle cells from whiskers of rats, labial parts on both right and left sides are aseptically cut out by a scalpel, and hair follicles in a growth period are extracted under a microscope and cut immediately above bulb parts of hair. Then hair papillae from the bulb parts of hair are cut out and cultured.
Tumor diagnostic specimens from patients who subsequently failed therapy within 4 years of diagnosis or who did not fail therapy within 4 years of diagnosis (control patients) are obtained from the Children's Oncology Group cellbank. Specimens are studied for molecular determinants of human reduced folate carrier (hRFC) gene expression and gene sequence alterations using reverse transcriptase-polymerase chain reaction (RT-PCR), thymidylate synthase inhibition assay, Rnase protection assay, or 5'RACE. Multidrug resistance proteins are also studied by RT-PCR.
PROBLEM TO BE SOLVED: To obtain the subject preparation capable of easily masking an unpleasant taste and securing excellent administration by making the preparation include a component having an unpleasant taste and cacao powder. SOLUTION: This composition contains a component having an unpleasant taste such as a vitamin (e.g. nicotinamide, calcium ASCORBATE, etc.), an iron compound (e.g. ferrous fumarate, ferric pyrophosphate, caffeine, etc., and (B) cacao powder (a substance obtained by fermenting cacao bean of the family Sterculiacae, drying, roasting and grinding to powder). In the composition, preferably 1 pt.wt. of the component A is mixed with 0.5-20 pts.wt. of the component B. The components are further mixed with (C) a sweetener (e.g. stevia extract, aspartame, dipotassium glycyrrhizinate, etc.), to increase the action of further masking an unpleasant taste. The amount of the component C mixed is preferably 0.001-0.01 pt.wt. based on 1 pt.wt. of the component A.
Group Lignocaine will receive an IV bolus dose of 1.5 mg/kg of 2% lignocaine HCL diluted up to 10 ml with normal saline in a 10 ml syringe which will be delivered via a syringe pump over a period of 3 min. This is then followed by an IV infusion at the rate of 1 mg/kg/h of 2% lignocaine HCL in a 20 ml syringe which will be administered by another syringe pump.
PROBLEM TO BE SOLVED: To provide a medical image data file device which speedily reproduces a specific file. SOLUTION: At least a patient ID (identification code) number, a photographing data and a file name are recorded in the directory area of an image file of a record medium disk. A disc insertion detector 37 detects that a disk has been loaded to a disk device 10. In response to the insertion of the disk, the list of directory information is prepared. As the list of directory information, a list in the order of the patient ID number and a list in the order of a date are prepared. A desired file is retrieved by using this list.
Objective: To evaluate the combined administration of propylthiouracil (PTU) and levothyroxine (LT4) in managing monocarboxylate transporter 8 (MCT8) deficiency and identify optimal therapeutic dosages. Methods: This multicenter case series involved 12 male patients with MCT8 deficiency whose parents/guardians consented to PTU and LT4 treatment. Data were collected from January 2008 to June 24, 2024. The study focused on treatment safety and outcomes, analyzing baseline and last encounter biochemical, metabolic, and anthropometric parameters. Statistical analyses included Wilcoxon signed ranks tests and generalized estimated equations to assess effects on thyroid and metabolic markers, and receiver operating characteristics curves to predict optimal dose. Results: Patients showed a significant reduction in serum total triiodothyronine (TT3) concentration and TT3/TT4 ratio, with increased serum TT4 and free T4 (fT4) concentrations. The use of PTU effectively reduced TT3 concentration by 25% at an average dose of 6.8 mg/kg/day, while LT4 increased fT4 concentration by 40% from baseline at an average dose of 4.3 µg/kg/day. Thyrotropin concentration was undetectable on treatment. No statistical differences were observed in metabolic and physical parameters between baseline and last encounter overall for the group, but six of eight patients for whom these data were available had an increase in weight (z-score). There were no adverse effects on liver function or granulocyte numbers noted throughout the period of observation. Conclusion: Combined treatment with PTU and LT4 normalized serum T3, fT4, and TT4 in patients with MCT8 deficiency. Individualized dose adjustments were crucial for achieving therapeutic goals, indicating the need for personalized treatment plans.
BACKGROUND: Nosocomial infections contribute significantly to mortality and morbidity in burn patients. Selective decontamination of the digestive tract is an infection prevention measure that has been shown to improve survival in mechanically ventilated intensive care unit (ICU) patients. It has been hypothesized that burn patients may benefit from selective decontamination of the digestive tract.
METHODS/DESIGN: We will conduct a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials (RCTs) assessing the patient-important effects of selective decontamination of the digestive tract in burn patients, as compared with placebo or no intervention/standard of care. The primary outcome will be 30-day mortality. Secondary outcomes include serious adverse events, anti-microbial resistance, pneumonia, blood stream infections, ICU- and hospital-free days and 90-day mortality. We will search the following databases: CENTRAL, MEDLINE, EMBASE, BIOSIS, Web of Science and CINAHL and follow the recommendations provided by the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The certainty of evidence will be assessed according to the GRADE approach: Grading of Recommendations Assessment, Development and Evaluation.
DISCUSSION: There is clinical equipoise about the use of selective decontamination of the digestive tract in burn patients. In the outlined systematic review and meta-analysis, we will assess the desirable and undesirable effects of selective decontamination of the digestive tract in burn patients.
PURPOSE: To obtain a cosmetic excellent in adhesivity and covering function on the skin and hair and dispersion to a product and having good feeling on use by using a basic amino acid of N-mono-long chain acyl having a specific average projected diameter. CONSTITUTION: This cosmetic is produced by using a basic amino acid of N- mono-long chain acyl having an average projected diameter of 0.01-3μm, preferably 0.1-1μm. The basic amino acid is obtained e.g. by dissolving a basic amino acid of N-long chain acyl in an alkaline solution of NaOH, etc., adding dropwise the obtained solution into a solution of hydrochloric acid, etc., to precipitate crystals (the pH is kept in the range of 2-5 during the addition and 2-6 after the addition), separating the precipitated crystals by filtration and washing them with water followed by drying. Thus obtained fine powdery basic amino acid of N-long chain acyl is preferably added into a cosmetic, e.g. in an amount of 0.1-99.1wt.% in a makeup cosmetic and 0.1-30wt.% in a body cosmetic.
BACKGROUND: Chronic pelvic pain is a burdensome condition that involves multiple medical sub-specialties and is often difficult to treat. Sacral stimulation for functional bladder disease has been well established, but little large-scale evidence exists regarding utilization of other neuromodulation techniques to treat chronic pelvic pain. Emerging evidence does suggest that neuromodulation is a promising treatment, and we aim to characterize the use and efficacy of such techniques for treating chronic pelvic pain syndromes.
MATERIALS AND METHODS: A systematic review of the literature demonstrating the treatment of chronic pelvic pain syndromes with neuromodulation. Abstracts were reviewed and selected for inclusion, including case series, prospective studies, and randomized controlled trials (RCTs). Case studies and publications in abstract only were not included. The reporting for this systematic review follows Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). The literature search was performed using MEDLINE, Embase, Cochrane Library, PubMed, CINAHL, and Scopus.
RESULTS: A total of 50 studies were included in this review, three of which were randomized controlled trials, and the remaining were prospective and retrospective case series. The range of pelvic pain conditions treated included interstitial cystitis, peripheral neuralgia, pudendal neuralgia, gastrointestinal pain, urogenital pain, sacroiliac joint pain, and visceral chronic pelvic pain. We reported on outcomes involving pain, functionality, psychosocial improvement, and medication reduction.
CONCLUSIONS: Neuromodulation is a growing treatment for various chronic pain syndromes. Peripheral nerve stimulation was the least studied form of stimulation. Posterior tibial nerve stimulation appears to offer short-term benefit, but long-term results are challenging. Sacral nerve stimulation is established for use in functional bladder syndromes and appears to offer pain improvement in these patients as well. Dorsal root ganglion stimulation and spinal cord stimulation have been used for a variety of conditions with promising results. Further studies of homogeneous patient populations are necessary before strong recommendations can be made at this time, although pooled analysis may also be impactful.
Tivozanib hydrochloride will be administered orally, at a dose of 1.5 mg/day, beginning on Day 1 of Cycle 1. Subjects will receive tivozanib hydrochloride once daily for 3 weeks followed by 1 week off treatment. One cycle is defined as 4 weeks. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicities.
Study participants will benefit from a plantar massage session (5-10 min foot massage) and one posture and walking workshop per week, supervised by a trained health professional. Minimalist shoes have been purchased by the centers and used during the workshops. They will also be available to participants outside the workshops for the duration of the study.
β-thalassemia represents a major public health problem in Egypt, it is estimated that there are 1000/1.5 million per year live births born with β-thalassemia. The average life expectancy of patients with β-thalassemia has improved over the last few years as compared to that of in the previous millennium. This has led to the discovery of new set of problems such as increased hypercoagulable state in β-thalassemia like micro infarcts in spleen and lung indicating an activated coagulation pathway. The, incidence of thromboembolism in patients with thalassemia disease is approximately 10 times higher than normal population, it accounts between 1.7 and 9.2%. On the other hand, a study conducted by Chaudhary and Ahmad, 2012 showed decreased aggregation in majority of β-thalassemia patients. Another study conducted by Ibrahim, 1999 had noticed few patients to have bleeding manifestations in the form of epistaxis. Mussumeci et al., 1987 noted that both thrombophilic and anti-thrombophilic proteins were reduced as a consequence of liver damage. The net clinical outcome depends on the fine balance between the prothrombotic and antithrombotic pathways.
PURPOSE: A cosmetic composition containing antiseptic substitute and natural plant extract is provided to ensure excellent antibacterial activity and prevent skin irritation with formulation stability. CONSTITUTION: A cosmetic composition contains 0.1-1.0 weight% of ethylhexylglycerin, 0.1-1.0 weight% of caprylic glycol, 0.001-10.0 weight% of Needle Juniper extract, 0.001-10.0 weight% of chives extract, and 0.001-10.0 weight% of Mosla japonica extract. The carpylic glycol and ethyl hexane glycerin is mixed in the ratio of 10:1-1:10. The extract is isolated using water, anhydrous or hydrous alcohol of 1-4 carbon atoms, acetone, ethyl acetate, chloroform or 1,3-butyleneglycol. The cosmetic composition is used for anti-inflammation and relieving skin irritation. The cosmetic composition is used in the form of emulsion, cream, gel, pack, cleansing cream, foam cleansing, foundation, mascara, eye shadow or eye liner.
The invention discloses a policosanol hair protection and hair growth agent and a preparation method thereof. The policosanol hair protection and hair growth agent comprises the following raw materials in parts by mass: 0.5-10 parts of a policosanol mixture and 99.5-90 parts of camellia oleosa seed oil. The preparation method comprises the following steps: adding the policosanol mixture to the camellia oleosa seed oil in a water bath with the temperature of 65-93 DEG C, stirring and cooling to room temperature after the policosanol mixture is completely dissolved in the camellia oleosa seed oil, thus obtaining the hair protection and hair growth agent. By virtue of the raw materials of which special efficacies are mutually supplemented and promoted, the hair protection and hair growth agent disclosed by the invention, compared with a chemically synthesized agent, has the advantages of low side effect, high safety, no toxin or harm, no carcinogenesis and the like. In addition, the policosanol mixture and the camellia oleosa seed oil are compounded to be applied to the hair growth agent for the first time, so that the range of plant-derived hair growth supplies is widened. Experiments prove that the hair growth agent disclosed by the invention has an effect of promoting hair growth.
Cystic fibrosis is the most common rare genetic disease in France, and in European countries in general. According to current epidemiological data, 80,000 people worldwide are affected. It represents a major public health issue, as it is a chronic disease that has a major impact on the life expectancy of affected patients. Thanks to the latest medical advances, promising treatments are now available, helping to improve patient survival rates to over 40-50 years. Among existing treatments, respiratory and musculoskeletal physiotherapy are highly recommended. It will play a key role throughout the life of a cystic fibrosis patient. Patients with chronic respiratory diseases are at high risk of developing anxiety and depressive symptoms. As the disease worsens, the patient becomes increasingly dependent, leading to restrictions in participation and activities of daily living. As a result, the presence of family and friends is of paramount importance in ensuring that sick children adhere to treatment and take their medication. However, this workload on the part of a parent, who has to make major changes to their lifestyle in order to adapt to their child's treatment, can have a considerable impact on their well-being, and increase the risk of anxiety/depression, even leading to burnout. Psychologists have studied the subject of assessing quality of life in parents of children with cystic fibrosis. At present, knowing that the quality of life of sufferers is as much affected as that of their caregivers, questionnaires have been introduced to assess parents' quality of life, notably the CarerQol-7D . The aim of this study would be to raise the issue of exhaustion among parents of children with cystic fibrosis, and to consider how to reduce the impact of this heavy mental burden on them. This would contribute to better therapeutic adherence and improved treatment of children. To this end, questionnaires and interviews could be set up with parents, with the aim of developing a relevant and optimal action strategy for their children.
The study design is cross-sectional. This study will be conducted at a single Magnet-designated facility, Methodist Richardson Medical Center (MRMC), within the Methodist Health System. The sample will be a convenience sample of hospital-registered nurses and para-professional nursing services staff (e.g., patient care technicians and specialty area technicians) who agree to participate in an online survey launched via the Survey Monkey® portal. Survey Monkey® is an online, cloud-based survey delivery portal, and the subscription for the use of the portal is paid for by the Department of Education (DOE) at MRMC. Hence, the data will be owned by MHS. The study is a one-time inquiry. The PI and designated sub-investigators will send institutional emails to staff members who meet the inclusion criteria. The timeline for the study will be a total of four weeks. The study will be introduced for one week, be available for three weeks, and will conclude by the end of week four.
A cohort of consisting of adults without a cancer diagnosis residing in the same residence as participants, will be consented to collect fecal microbiome specimens to serve as a control for potential regional variation in microbiome dysbiosis. Up to 25 healthy controls will be enrolled per 100 participants at each study site. At sites enrolling fewer than 100 participants, an n up to 25% of the total patient enrollment sample will be approached for enrollment.
Control patients will engage in a 16-week program where they will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity. Patient-reported outcomes measures will be collected pre-and-post-intervention.
Peritonitis, a serious complication of peritoneal dialysis (PD), can be caused by opportunistic pathogens like Micrococcus species on rare occasions. We present a case of Micrococcus sp peritonitis in a 55-year-old female with end-stage kidney disease on continuous cycling peritoneal dialysis for one year who presented with cloudy effluent. Initial treatment against Micrococcus sp with vancomycin, gentamicin, and prophylactic oral nystatin was successful. However, one month later, the patient presented with abdominal pain and dialysate culture again grew Micrococcus sp. Treatment with vancomycin was unsuccessful in resolving culture positivity. The patient was transitioned to hemodialysis for non-medical reasons and then was later restarted on PD without further peritonitis episodes. Micrococcus sp peritonitis in PD poses treatment challenges due to limited guidelines. Intraperitoneal vancomycin is commonly used to target Micrococcus isolates although there is a high incidence of treatment failure. This case report highlights the need for continued reporting to enhance identification, prevention, and patient outcomes in Micrococcus sp peritonitis during PD.
Parkinson disease (PD) psychosis (PDP) is a spectrum of illusions, hallucinations and delusions that are associated with PD throughout its disease course. Psychotic phenomena can manifest from the earliest stages of PD and might follow a continuum from minor hallucinations to structured hallucinations and delusions. Initially, PDP was considered to be a complication associated with dopaminergic drug use. However, subsequent research has provided evidence that PDP arises from the progression of brain alterations caused by PD itself, coupled with the use of dopaminergic drugs. The combined dysfunction of attentional control systems, sensory processing, limbic structures, the default mode network and thalamocortical connections provides a conceptual framework to explain how new incoming stimuli are incorrectly categorized, and how aberrant hierarchical predictive processing can produce false percepts that intrude into the stream of consciousness. The past decade has seen the publication of new data on the phenomenology and neurobiological basis of PDP from the initial stages of the disease, as well as the neurotransmitter systems involved in PDP initiation and progression. In this Review, we discuss the latest clinical, neuroimaging and neurochemical evidence that could aid early identification of psychotic phenomena in PD and inform the discovery of new therapeutic targets and strategies.
This is a multi-center, comparative, adaptive, non-significant risk clinical trial conducted in the United States to assess the safety and efficacy of the Tango Belt within senior care settings. Effectiveness of the Tango Belt will be determined by analysis of evidence for the Tango Belt as an adjunctive intervention to the standard-of-care (SOC) to mitigate major hip injuries from falls in an older adult population at-risk for fall injury as the primary endpoint. Performance of the Tango Belt to mitigate fall injuries that result in hip fracture, emergency room visits, and hospitalizations will be secondary endpoints. The performance of the device is determined by the comparison of the proportion of fall-related major hip injuries in the intervention group as compared to the proportion of fall-related major hip injuries in a retrospective control group utilizing only SOC. SOC utilization will be verified for each clinical site enrolled. An adaptive trial design will be utilized to allow an initial efficacy target to be evaluated at 6 months; if the initial target is not met, then a second cohort of sites and subjects will be enrolled for an additional 6 months to allow a lower efficacy target to be evaluated.

Safety of the device will be determined by analysis of adverse events as an ancillary endpoint.